Abstract :
The most common sign of Autosomal dominant polycystic kidney disease (ADPKD) is the development of multiple kidney cysts over time, which eventually lead to end-stage kidney disease (ESKD) and require renal replacement therapy. To treat ADPKD, several treatments have been developed. However, not all these remedies have been effective in preventing the development of the disease. It is essential to have a thorough knowledge of the mechanisms leading to cyst formation and growth before diving into specific therapy for controlling ADPKD. Numerous clinical trials are undergoing over the past two decades aiming to treat ADPKD as a result of significant research efforts. Tolvaptan is the only pharmaceutical agent found to be successful in delaying the deterioration of kidney function in ADPKD, even though Tolvaptan has several undesirable side effects, including thirst, polyuria, and liver damage when used for an extended period. In this review, we have covered the detailed pathophysiology and molecular mechanisms of PKD, as well as the possibility of emerging therapies in the clinical development of PKD.
Keyword :
Autosomal dominant polycystic kidney disease, End-stage kidney disease, Emerging therapies